Allogeneic bone marrow transplantation using partially-matched related donors

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic bone marrow transplantation (BMT) is a critical treatment for advanced leukemia and severe combined immunodeficiency syndrome.
• Identifying suitable HLA-matched donors remains a significant challenge, limiting BMT accessibility.

Purpose of the Study:

• To evaluate the efficacy and outcomes of allogeneic BMT using HLA-haploidentical donors with one or two loci compatibility on the non-shared chromosome.
• To assess the potential of partially matched related donors in expanding BMT applications.

Main Methods:

• Six patients with advanced leukemia and one with severe combined immunodeficiency syndrome underwent allogeneic BMT.
• Donors were HLA-haploidentical and compatible for one or two loci on the non-shared chromosome.
• Methotrexate was administered for prophylaxis against acute graft-versus-host disease (GVHD).

Main Results:

• Allogeneic bone marrow transplantation (BMT) recipients achieved engraftment.
• Moderate to severe acute graft-versus-host disease (GVHD) developed in all patients, with three deaths.
• Two leukemic patients relapsed, while two achieved long-term disease-free survival (403 and 936 days post-transplant).

Conclusions:

• Allogeneic bone marrow transplantation (BMT) using related partially matched donors can result in durable engraftment and long-term survivors.
• Partially matched related donors represent a viable option for expanding BMT accessibility.
• Further research is warranted to optimize GVHD prophylaxis and improve outcomes in this patient population.